Chronic Spontaneous Urticaria (CSU)
Dermatology
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2025
2026
2027
2028
InnoCareICP-332 Tablets
CelltrionOmalizumab
Clinical Trials (2)
Total enrollment: 569 patients across 2 trials
Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
Start: Mar 2026Est. completion: Sep 2028344 patients
Phase 2/3Not Yet Recruiting
ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab Biosimilar
Start: Oct 2025Est. completion: Sep 2028225 patients
N/ARecruiting
Related Jobs in Dermatology
MSL/Senior MSL, Dermatology - Tampa, Florida
AbbVie
Remote
11h ago
(Senior) Außendienstmitarbeiter Dermatology (all genders) - Region Thüringen
AbbVie
Remote
11h ago
Regional Sales Trainer - Dermatology (Central / West Regions)
AbbVie
Remote
12h ago
Regional Sales Trainer - Dermatology (Northeast / Southeast Regions)
AbbVie
Remote
12h ago
Delegado Especialista Ventas Dermatología (Inmunología)
AbbVie
Remote
17h ago
Senior Manager, HTA, Value and Evidence (HV&E), Medical Dermatology
Pfizer
United States - New York - New York City
Yesterday
$139K - $232K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 569 patients
Monoclonal Antibody is the dominant modality (100% of programs)
2 companies competing in this space